Functional Autoantibodies Targeting G-Protein-Coupled Receptors and Their Clinical Phenotype in Patients with Long-COVID

By SWA

Introduction:

Long-COVID, characterized by persistent symptoms following acute SARS-CoV-2 infection, has emerged as a complex and multifaceted condition affecting a significant proportion of recovered patients. While the pathophysiology of Long-COVID remains incompletely understood, growing evidence suggests that dysregulation of the immune system plays a central role. A recent German contact study (Published: 14 July 2025) 
has identified the presence of functional autoantibodies targeting G-protein-coupled receptors (GPCRs) in individuals suffering from Long-COVID. These autoantibodies, which have been implicated in various autoimmune and neurovascular disorders, may contribute to the wide spectrum of symptoms reported by Long-COVID patients, including fatigue, cognitive impairment, cardiovascular abnormalities, and dysautonomia. This study explores the clinical relevance of GPCR-targeting autoantibodies and their potential role in defining the immunological and symptomatic phenotype of Long-COVID, offering new insights into diagnosis and potential therapeutic strategies.

Explanation:
G-protein coupled receptors (GPCRs) are a large family of proteins found in cell membranes that play a crucial role in cellular signaling by transmitting signals from outside the cell to the inside. They are involved in a wide array of physiological processes, including sensory perception, hormone regulation, neurotransmission, and immune response. Dysregulation of GPCR signaling is implicated in various diseases, such as cardiovascular disorders, diabetes, depression, and cancer.

GPCRs and Disease:

    Cardiovascular Diseases:

    GPCRs, particularly those for hormones and neurotransmitters, are heavily involved in regulating heart function and blood pressure. For example, beta-blockers, which target β-adrenergic receptors (a type of GPCR), are used to treat hypertension and heart failure. Angiotensin II receptor blockers (ARBs), another GPCR-targeting drug, are also used for hypertension.

Diabetes:

GPCRs are involved in glucose homeostasis and insulin secretion. Drugs that target GPCRs involved in these processes are used to treat type 2 diabetes.

Depression and Mood Disorders:

Certain GPCRs, including those for neurotransmitters like serotonin and dopamine, are involved in mood regulation. GPCRs are also implicated in the mechanism of action of some mood stabilizers.

Cancer:

GPCRs can influence cancer cell growth, metastasis, and angiogenesis (formation of new blood vessels). Some GPCRs are overexpressed in certain cancers and are being explored as potential drug targets.

Inflammatory Diseases:

GPCRs play a role in inflammation by regulating the migration of immune cells and the production of inflammatory mediators. GPCRs involved in inflammatory responses are potential targets for anti-inflammatory drugs.

Pain:

GPCRs are involved in pain transmission and modulation, making them important targets for pain management. Opioid receptors, which are GPCRs, are targeted by opioid analgesics.

Infections:

Viruses can encode their own GPCRs (vGPCRs) to manipulate host cell signaling and evade the immune system. Understanding vGPCRs can help in developing antiviral therapies.

Major Clinical Symptoms Associated with GPCR Dysregulation:

The clinical symptoms associated with GPCR dysregulation vary widely depending on the specific receptor and its location in the body. Some examples include:

    Cardiovascular: High blood pressure, chest pain, shortness of breath, irregular heartbeat.

    Metabolic: Increased thirst and urination, fatigue, unexplained weight loss or gain.

    Neurological/Psychiatric: Depression, anxiety, sleep disturbances, cognitive impairment.

    Inflammatory: Pain, swelling, redness, fever, fatigue.

    Infectious: Fever, fatigue, inflammation, tissue damage.

Drug Development:

GPCRs are a major class of drug targets, and many medications work by modulating GPCR activity.
Examples include antihistamines, beta-blockers, and various psychiatric medications. Research is ongoing to develop new drugs that target GPCRs with greater specificity and fewer side effects.

References:

Functional Autoantibodies Targeting G-Protein-Coupled Receptors and Their Clinical Phenotype in Patients with Long-COVID
https://www.mdpi.com/1422-0067/26/14/6746

G protein-coupled receptors: structure- and function-based drug discovery
https://www.nature.com/articles/s41392-020-00435-w

G Protein-Coupled Receptors in Major Psychiatric Disorders
https://pmc.ncbi.nlm.nih.gov/articles/PMC2366056/#:~:text=3.5%20G%20protein%2Dcoupled%20GABAergic%20receptors%20and%20mood,to%20their%20pharmacologic%20effect%20is%20not%20known.

 G-Protein–Coupled Receptors in Heart Disease
https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.118.311403#:~:text=Abstract.%20GPCRs%20(G%2Dprotein%20%5Bguanine%20nucleotide%2Dbinding%20protein%5D%E2%80%93coupled%20receptors),hypertension%2C%20coronary%20artery%20disease%2C%20and%20heart%20failure


© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742

Comments

Post a Comment

Popular posts from this blog

Schnitzler Syndrome: A Rare Autoinflammatory Disorder

By SWA
Schnitzler syndrome is a rare, chronic autoinflammatory disease characterized by chronic urticaria (hives), recurrent fever, joint pain, and monoclonal gammopathy (abnormal proteins in the blood). First described by Dr. Liliane Schnitzler in 1972 , this condition is often misdiagnosed, leading to years of untreated symptoms before a correct diagnosis is made. The case report, " A 58-Year-Old Woman With Urticaria, Fever, and Joint Pain " , describes a case that closely aligns with my own experience with this challenging disorder. Key Features of Schnitzler Syndrome Schnitzler syndrome presents with a characteristic set of symptoms, though not all patients experience them in the same way: Chronic Urticaria (Hives) – Persistent, non-itchy or mildly itchy red patches that do not respond to antihistamines. Monoclonal Gammopathy (IgM or IgG type) – Abnormal monoclonal immunoglobulin detected in the blood (most commonly IgM ). Recurrent Fever – Unexplained fever episodes, often...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Very Long-Chain Fatty Acids (VLCFAs) X-ALD and Spinal Muscular Atrophy (SMA): Exploring the Connection

By SWA
Update Oct 28th 2024:  A Novel Mouse Model for Cerebral Inflammatory Demyelination in X-Linked Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic Targets https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.27117 Very Long-Chain Fatty Acids (VLCFAs) are a specific type of fatty acid that are broken down in the body by specialized cellular structures called peroxisomes. These organelles play a critical role in maintaining metabolic balance by degrading VLCFAs. When this process is disrupted, VLCFAs accumulate in various tissues, which can lead to serious metabolic and neurological complications. Elevated VLCFA levels are characteristic of several peroxisomal disorders, most notably X-linked Adrenoleukodystrophy (X-ALD) and Zellweger Syndrome. In X-ALD, for example, a genetic defect impairs the peroxisomal breakdown of VLCFAs, resulting in their accumulation in the brain, spinal cord, and adrenal glands. This buildup can cause progressive neurological damag...
Read more